LianBio Q3 net loss $24M, inks $350M BMS mavacamten deal, strategic review ongoing

LianBio

2023-Q3 EPS reported -$0.65 vs consensus -$0.34 ▼ miss (-91.2%)

Net loss of $24.0M in Q3 2023 vs $21.9M loss in Q3 2022; cash $252.2M as of Sep 30, 2023.
Entered agreement with BMS for mavacamten rights in China and other Asian markets for $350M total consideration.
Phase 3 TP-03 for Demodex blepharitis: mite eradication significant (p<0.001), collarette cure not significant (p=0.15); plans NDA filing.
Board initiated comprehensive strategic review in October 2023; update expected first half 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LianBio reported the third quarter ended September 30, 2023 results: net income Net loss was $24.0 million for the third quarter of 2023.

Period: the third quarter ended September 30, 2023
Net income: Net loss was $24.0 million for the third quarter of 2023
Result: reported results

Exact text from the filing

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the third quarter ended September 30, 2023.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

LianBio filing history →

Source: SEC EDGAR

accession 0001831283-23-000124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.